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Background: Infection is a common cause of death in patients with cirrhosis. We investigated the association between the innate immune response and death within 3 months of hospitalization.
Findings: In an analysis of plasma samples from patients given albumin infusions for acute decompensated cirrhosis or acute on chronic liver failure, we found differences in levels of cytokines in patients who survived 30 days vs patients who did not. Plasma from survivors had increased levels of interleukin 4, which reduced activation of monocyte-derived macrophages. Plasma levels of prostaglandin E2 decreased with albumin treatment.
Implications for Patient Care: Differences in plasma levels of cytokines, such as prostaglandin E2 and interleukin 4, might affect response to infections or treatment in patients with acute decompensated cirrhosis or acute on chronic liver failure.
INTRODUCTION
The most severe clinical presentation of liver cirrhosis is acute decompensation (AD) or Acute-on-Chronic-Liver Failure (ACLF) 1 . Patients are highly prone to bacterial infection secondary to immune dysregulation 2 termed 'cirrhosis-associated immune dysfunction' or CAID 2 . CAID causes a paradoxical phenotype in ACLF that combines exaggerated systemic inflammation with immune suppression. Potential immune restorative therapies should aim to improve immune function without worsening systemic inflammation; however, despite detailed work describing the ACLF phenotype 3, 4 and its high clinical relevance, there are no licensed treatments to improve immune dysfunction.
We previously identified Prostaglandin E 2 (PGE 2 ) as a potential causative immune suppressive molecule 5, 6 . Albumin has been reported to bind and catalyse PGE 2 inactivation 7 and we found that as albumin levels decreased in AD/ACLF, PGE 2 may be more bioavailable and injurious. We therefore proposed transfusing 20% human albumin solution (HAS) to antagonise the effects of PGE 2 6 and prevent infection in our randomised controlled trial (RCT), ATTIRE (Albumin to prevent infection in chronic liver failure). In the single arm ATTIRE feasibility study of 79 patients at 10 sites, we demonstrated that 20% HAS infusions restored serum albumin levels to >30 g/dl and improved ex vivo immune function in AD/ACLF patients by day 3 of study participation through antagonism of PGE 2 6, 8 . However this study included samples from only the first few days of admission and was not linked with clinical outcome.
We therefore performed this follow-up study examining the inflammatory response throughout admission in albumin-treated patients and linked this to outcome. We selected mortality at 3 months following recruitment as our primary clinical outcome in order to study whether the inflammatory response throughout admission differed between survivors and non-survivors and potential underlying molecular mechanisms.
Our study suggests that survivors and non-survivors exhibited distinct temporal profiles in immune function that corresponded with changes in white cell count and we propose a novel role for interleukin (IL)-4 in this process.
METHODS

Patient studies
Patients were recruited as part of the ATTIRE feasibility study, all were treated with daily intravenous (IV) 20% HAS if serum albumin <30g/L during the trial treatment period (up to 14 days post recruitment). All patients admitted to hospital with AD/severe worsening of liver cirrhosis complications, aged >18years, serum albumin <30g/L, predicted hospital admission by attending clinicians greater than 5 days and for full active management at admission were eligible. Patients were recruited within 72 hours of hospitalisation; full criteria are described elsewhere 8, 9 . We sought written informed patients consent from patients or representatives Experimental studies were performed on samples available with n values in figure legends.
The trial is registered with European Medicines Agency (EudraCT 2014-002300-24) and adopted by NIHR (ISRCTN14174793). All authors had access to the study data and reviewed and approved the final manuscript.
Laboratory analysis are described in Supplemental Material. For multiple comparisons, significance was assessed by one-way ANOVA followed by Bonferroni adjusted pairwise ttests. White cell count and CRP followed an approximately log-normal distribution each day and values were therefore transformed (ln, natural logarithm) for statistical analyses.
Number of tests were adjusted for the number of trial days. Differences in mean values between survivors and non-survivors were compared using two-tailed t-test allowing for unequal variances with Bonferroni correction.
RESULTS
Distinct plasma-mediated inflammatory response phenotypes during hospitalisation in albumin-treated patients differentiated between survivors and non-survivors
We investigated the temporal profile of inflammatory responses in participants throughout the trial period, by examining the effect of plasma from days 1, 5, 10 and 15 on healthy monocyte derived macrophages (MDMs) 5, 6 . MDMs were incubated with plasma from AD/ACLF patients or healthy volunteers and subsequent activation in response to LPS quantified by assessing levels of secreted TNF-α. As previously 6 , plasma from AD/ACLF patients at day 1 reduced MDM TNF-α production compared to healthy volunteer plasma ( Figure 1A ). This immune suppressive effect waned during hospitalisation and, following targeted HAS infusions, reached healthy volunteer levels by end of trial treatment period (day 15) ( Fig 1A) . MDM production of the anti-inflammatory cytokine IL-10 at 24 hours poststimulation mirrored this pattern with levels higher at day 1 and returning to those produced by cells incubated with healthy plasma by day 15 ( Fig 1B) .
When samples were divided into survivor and non-survivors, this observed pattern of immune activation differed between groups. MDMs sensitised with day 1 non-survivor plasma demonstrated a slightly lower production of TNF-α compared to survivors ( Fig 1C) .
However, MDM TNF-α production in this group was rapidly and significantly restored to healthy levels by day 5 and maintained throughout the rest of the trial. In contrast, MDM TNF-α production following treatment with survivor plasma did not reach healthy plasma levels until day 15 of the trial ( Fig 1C) . Indeed, there was a 2.6 fold-increase in TNF-α levels between day 1 and day 5 in cells incubated with non-survivor plasma (p < 0.001) compared to 1.26 fold-increase in those treated with survivor plasma (p > 0.05). Neither patient group's plasma elicited a greater TNF-α production than healthy volunteer plasma by day 15 of trial ( Fig 1C) . These distinct patterns of inflammatory response between survivors and nonsurvivors were mirrored by MDM production of IL-10 ( Fig. 1B) . Survivor plasma elicited a gradual decrease in MDM IL-10 production to reach the same level as healthy volunteer plasma by day 15, whereas non-survivor plasma elicited a more rapid fall in production by day 5, although differences did not reach significance ( Fig 1D) . These two inflammatory response phenotypes (rapid in non-survivors compared to gradual in survivors), appeared distinct by day 5 of the trial, marking this as a potential crucial time-frame that determines outcome. We therefore focused further analyses between baseline (day 1) and day 5.
Both groups of patients demonstrated similar baseline clinical characteristics but non-survivors developed increased serum white cell counts, C-reactive protein and renal dysfunction
Overall baseline patient data has been presented previously in this cohort with the majority having alcohol-related cirrhosis 8 . Non-survivors displayed non-significantly increased Model for End Stage Liver Disease (MELD) scores, ACLF scores, diagnosis of infection at baseline and antibiotic prescription ( Table 1 ). The number of days in trial, baseline white cell count (WCC) and C-Reactive protein (CRP) were similar in both groups ( Table 2) . Serum creatinine was higher in non-survivors at baseline and renal dysfunction developed solely in the non-survivor group (30.8%, Table 1 ). As the differences in laboratory inflammatory response appeared during the first half of the trial, we compared the WCC and CRP values between groups during this period (up to day 7). On day 6 where the difference in WCC levels between groups reached its peak ( Fig. 2A ) the absolute WCC levels were significantly higher in non-survivors (p=0.029). Relative change from baseline WCC also significantly differed on day 6 between survivors and non-survivors (adjusted p=0.033, corrected for 4 tests, raw p=0.008) when values were compared. CRP followed a similar trend with higher levels in non-survivors, but differences in absolute levels did not reach statistical significance, however the difference in relative change from baseline CRP significantly differed between groups on day 4 (adjusted p=0.032, corrected for 2 tests, raw p=0.016) ( Fig   2B) . Nosocomial infections developed in 10/26 non-survivors compared to 9/45 survivors following 48 hours of albumin treatment (p=0.19, chi-squared test).
Plasma levels of albumin, LBP and albumin-PGE 2 binding capacity during hospitalisation did not differ between survivors and non-survivors
Volume of HAS administered during the trial did not differ between survivor and non-survivor groups ( Table 1 ) and levels of circulating albumin and its binding capacity to PGE 2 improved similarly in both groups throughout the trial ( Fig 2C) . Levels of plasma LPS-binding protein (LPB), used as a marker of endotoxin presence 10 , did not differ between groups ( Fig 2D) .
Plasma lipid mediator profiles at day 1, 5, 10 and 15 differed between survivors and non-survivors
Lipid mediator (LM) analysis revealed differing trends between inflammation-initiating and resolution pathways in survivors and non-survivors according to day of sampling. We amounts of these molecules did not reach statistical significance (Suppl Table 1 ).
Plasma LM profiles demonstrated PGE 2 concentrations were similarly elevated levels at day 1 ( Fig 3A,B ) (p=0.47) and fell substantially by day 5 in both groups (p=0.09). When cells incubated with day 5 plasma from both survivors and non-survivors were treated with pan-PGE 2 receptor antagonists, there was a similar increase in MDM TNF-α production (1.2-fold change for both groups) ( Fig 3C) .
Elevated plasma IL-4 concentration at day 5 was associated with 3-month survival and was able to switch plasma-mediated inflammatory response
We measured 30 cytokines in survivor and non-survivor plasma from days 1, 5, 10 and 15 by multiplex analysis (Suppl Table 2 ). No differences were observed between groups of the classical inflammatory cytokines linked to ACLF prognosis 11, 12 , such as TNF-α, IL-6, IL-8
and IL-10 (Suppl Figure 2A) . A significant increase in IL-4 was found in survivor day 5 plasma ( Fig 3D) , the period at which survivor and non-survivor plasma-mediated inflammatory response phenotypes appeared distinct. Western blot analysis revealed that peripheral blood mononuclear cells (PBMCs) from AD/ACLF patients contained detectable levels of IL-4 protein (Suppl Figure 2B ). Subsequently, we demonstrated that MDMs incubated with healthy volunteer plasma that had been supplemented with increasing concentrations of recombinant IL-4 caused decreased TNF-α production in response to LPS in a dose-dependent manner (Fig. 3E ). MDM cells treated with day 5-survivor plasma that had been pre-incubated with neutralizing anti-IL-4 antibody (black and white squared box), significantly increased TNF-α production and this reached the same level as seen in cells incubated with non-survivor plasma (light grey box) ( Fig. 3F ). No effect was seen with neutralizing anti-IL-4 antibody in experiments using non-survivor plasma (Fig. 3F ). Finally, we observed that IL-4 plasma concentrations at day 5 correlated negatively with baseline MELD score (Suppl Fig 3) .
DISCUSSION
Immune function and inflammation in AD/ACLF patients has emerged as a critical area of research with the aim of developing treatments that improve mortality 13 . Due to challenges associated with collecting primary cells from multiple sites, we used our ex-vivo immune assay to investigate plasma-mediated immune responses and sought to determine whether results were associated with 3-month mortality. These data demonstrate that HAS infusions continued to restore the plasma-mediated inflammatory response as defined by macrophage TNFα and IL-10 production in AD/ACLF patients to healthy volunteer levels beyond day 3 as shown previously 6, 8 . This is consistent with recent data identifying changes in plasma IL-10 reflecting disease severity and improving following albumin treatment 4, 14 . Survivors and nonsurvivors demonstrated distinct and unexpected plasma-mediated inflammatory response patterns during the trial, with non-survivors exhibiting a rapid increase of MDM activation to healthy levels that associated with an elevated white cell count. Despite a significant overall effect on our immune assay, the HAS-PGE 2 interaction did not appear to differentiate between these inflammatory phenotypes. Intriguingly, IL-4 at day 5 was significantly upregulated in survivors and mechanistic analyses suggest this may also represent a potential therapeutic target. Finally, a failed resolution of inflammation lipid mediator phenotype was observed in non-survivors.
Our novel data support a mechanistic protective role for IL-4. This cytokine has not been previously linked to CAID, although studies in humans and animal models support a protective role for elevated IL-4 in sepsis 15 16 and acute lung injury 17 . We demonstrated that manipulation of IL-4 switched immune restoration-like phenotypes between survival and nonsurvival and suggest IL-4 agonism may represent a potential immune-restorative target in AD/ACLF patients that develop increased circulatory inflammatory markers during hospitalisation.
Previous studies demonstrated an association between high circulatory inflammatory markers e.g. CRP 18, 19 and inflammatory cytokines at baseline 12, 20, 21 and increased mortality in AD/ACLF. In our cohort baseline clinical characteristics of the survivors and non-survivors were quite similar aside from serum creatinine and a non-significant increase in MELD score and infection rate, which may be due to the relatively small sample size. However the development of an elevated WCC, CRP and renal dysfunction during admission was significantly associated with 3 month mortality. Our work supports elevated PGE 2 being crucial in this process early in admission and IL-4 at later timepoints, although it is likely that other molecules are involved.
We previously showed that albumin treatment may alter plasma LM profiles in a small cohort of patients from the ATTIRE feasibility study 6 . In this study Principal Component Analysis revealed several families of SPMs that associated with good or poor outcome using samples taken at different time points before and after albumin infusions. This work remains promising but greater numbers of patients will be required to identify specific LMs for potential drug development targets or to predict outcome or response to treatment. The observation that SPMs are also upregulated in non-survivors indicates that while SPM biosynthetic pathways are active in these patients, production does not limit the unbridled inflammatory response. This could be due to delayed engagement of biosynthetic pathways, dysregulated receptor expression or dysregulated downstream signalling pathways.
Many studies have demonstrated the potential immunomodulatory properties of albumin 5, 6, 22 . However differing results from recent well-conducted outpatient studies suggest patient response may not be uniform 23, 24 . All patients in this single arm study were treated with intravenous HAS which appeared to have a beneficial immune effect throughout hospitalisation by antagonising PGE 2 effects. However it is possible that the differing inflammatory responses observed associated with patients' 3 month outcome may represent albumin treatment "successes" and "failures". Further studies are required to determine whether PGE 2 levels early in admission, IL4 levels at day 5 or a LM failure to resolve phenotype represent biomarkers or targets for a future precision medicine approach to improve treatment in these patients. This was a single arm study and we were unable to compare findings with non-treated patients.
Our immune assay was developed to investigate effects of plasma from AD/ACLF patients on macrophage function rather than primary cells, as it was not possible to collect fresh monocytes from multiple UK sites. However, our separate single site study has demonstrated an identical phenotype of reduced TNF-α production in fresh whole blood from AD/ACLF patients stimulated with LPS, supporting this approach 25 . Furthermore our laboratory assay was potentially able to differentiate between survivors and non-survivors and mechanistic work has identified a potential novel mediator of CAID, suggesting that the approach has validity. The association of the inflammatory phenotype in those who died at 3 months with development of an elevated WCC and CRP strengthens the laboratory work and aids potential clinical approaches in the future. Our cohort predominantly included patients with alcohol-driven liver disease and the laboratory analyses used samples from only patients with alcohol-related cirrhosis. Therefore our findings may not be applicable to cohorts containing large numbers of non-alcoholic steatohepatitis or viral hepatitis patients.
Moreover we did not have sufficient samples to extend studies to compare between AD and ACLF. ATTIRE stage 2, a large scale RCT at 30 sites that finishes in June 2019 26 will provide samples taken from patients treated with and without HAS at day 1, 5 and 10 in order to validate these findings and guide future immune restorative approaches in AD/ACLF. This will allow us to discern the potential effect of 20% HAS infusion on the establishment of different patterns of inflammatory responses observed and their relationship to survival.
We present novel data that describes CAID as a dynamic process and propose that the inflammatory response trajectory may represent the critical determinant of clinical outcome.
Distinct plasma-mediated inflammatory responses, as defined by our laboratory assay and changes in WCC and CRP from baseline during the first week of hospitalisation, were associated with organ dysfunction and death in albumin-treated advanced liver disease patients. Finally our results PGE 2 and IL-4 as pivotal mediators that underlie the inflammatory response in these patients at different time points during their hospital admission. 
SUPPLEMENTAL METHODS
Criteria for decompensation of liver cirrhosis
These were defined as acute onset or worsening of complications of cirrhosis including gastroesophageal haemorrhage, jaundice, alcoholic hepatitis, ascites, hepatic encephalopathy, sepsis or infection including spontaneous bacterial peritonitis, hepatorenal syndrome or renal dysfunction.
Renal dysfunction was defined as an increase in serum creatinine level by ≥50% compared to creatinine level at baseline. Infection was defined as when a patient was prescribed a new antibiotic(s) and clinical data was recorded to subsequently categorise infection according to standard international criteria 1 . Both of these endpoints were recorded no earlier than 48 hours after the onset of albumin treatment.
Monocyte-derived macrophages (MDM) ex-vivo immune function assay
MDMs obtained from healthy volunteers 2,3 were sensitized with plasma for 30 minutes at 37 °C and then stimulated with 100 ng/ml of lipopolysaccharide (LPS, Salmonella abortus equi S- Plasma lipid mediators levels were quantified by High Performance Liquid Chromatography as described in 3 .
Western Blotting
Peripheral blood mononuclear cells (PBMC) were obtained from acutely decompensated 
Statistical analysis
Unless stated otherwise, data are presented as mean ± Standard Deviation (SD). . Two-tailed (unpaired) t-tests were performed when comparing two independent groups of values where a normal distribution was reasonable to assume. 
Supplemental
